Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive~* Naïve to antiretroviral therapy including investigational antiretroviral agents~* Not of reproductive potential or, if of reproductive potential agrees to 1) true abstinence, or 2) use of an acceptable method of birth control during the study~Exclusion Criteria:~* Use of recreational or illicit drugs or has recent history of drug or alcohol abuse or dependence~* Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with an agent that is active against HIV-1 including but not limited to adefovir, tenofovir, entecavir, emtricitabine, or lamivudine~* Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovir before the first dose of study drug~* Has participated in a study with an investigational compound or device within 30 days or anticipates participating in such a study during this study~* Has used systemic immunosuppressive therapy or immune modulators within 30 days or is anticipated to need them during the study (short courses of corticosteroids are allowed)~* Requires or is anticipated to require any of the following prohibited medications while in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium, magnesium and aluminum containing antacids, such as TUMS™, Maalox™ and Milk of Magnesia™~* Has significant hypersensitivity or other contraindication to any of the components of the study drugs~* Has current, active diagnosis of acute hepatitis due to any cause~* Is pregnant, breastfeeding, or expecting to conceive during the study~* Female participant expecting to donate eggs or male participant expecting to donate sperm during the study~* Is or has a family member (spouse or children) who is investigational staff or sponsor staff directly involved in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reformulated Raltegravir (Type: EXPERIMENTAL): Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
- Raltegravir (Type: ACTIVE_COMPARATOR): Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).